Structure's GLP-1 pill is safe, but diabetes efficacy lags Lilly's asset

Although its efficacy in diabetes fell below expectations, analysts were encouraged by GSBR-1290’s clean safety and efficacy among obesity patients.

Related Keywords

Switzerland , Swiss , David Risinger , Lilly Mounjaro , Raymond Stevens , Eli Lilly , Novo Nordisk Wegovy , Astrazeneca , Pfizer , Reuters , Structure Therapeutics , Novo Nordisk , Carmot Therapeutics ,